Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly influences sleep-wake cycles and stress-related neurochemistry in animal models.
The study, published in the International Journal of Neuropsychopharmacology, showed that ADX71743 increased wakefulness while reducing both REM and non-REM sleep in rats. It also altered stress-induced changes in neurotransmitters such as glutamate, GABA and monoamines, across multiple brain regions, producing effects consistent with modulation of stress-responsive neural circuits.
Tim Dyer, CEO at Addex, said the findings "add another important piece of evidence supporting the therapeutic potential of targeting these receptors with allosteric modulation," noting that the data further strengthen the rationale for Neurosterix's ongoing development of the mGlu7 program.
Previous studies have already demonstrated that selective mGlu7 inhibition can modulate anxiety-related behaviors, disrupt maladaptive fear memory reconsolidation and influence glutamatergic signaling in both rodent and human brain tissue.
ADX71743, discovered by Addex, has served as the prototype molecule underpinning numerous publications exploring mGlu7's therapeutic potential across anxiety, stress-related disorders, sleep regulation, fear memory, and visceral pain. The program is now being advanced by Neurosterix, a neuroscience company launched by Addex and Perceptive Advisors in 2024.
Addex continues to develop a portfolio of small-molecule allosteric modulators for neurological disorders, with dipraglurant (mGlu5 NAM) under evaluation for brain injury recovery and GABAB PAM programs advancing in substance use disorders and chronic cough.
ADXN has traded between $5.41 and $12.05 over the past year. The stock closed Tuesday's trading at $5.79. In pre-market trading the stock is at $6.19, up 6.91%.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.